Ads
related to: merck & co.
Search results
Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study
Morningstar· 7 hours agoMerck & Co. has ended part of a late-stage study of a co-formulation of its blockbuster cancer drug Keytruda in certain skin-cancer patients because the ...
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma...
Benzinga via Yahoo Finance· 2 hours agoMonday, Merck & Co Inc (NYSE:MRK) announced the discontinuation of the vibostolimab and...
Merck halts phase 3 TIGIT trial after immune-mediated adverse events prompt discontinuations
FierceBiotech· 6 hours agoMerck & Co. has bailed early on a phase 3 test of the anti-TIGIT antibody vibostolimab after a high...
Merck Expands Access to High-Quality Maternal Care for More
3BL CSRwire· 7 hours agoMerck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Merck for Mothers, the company’s global maternal health initiative, has reached more than 30 million ...
Merck stops skin cancer combination therapy testing in late-stage study
Reuters· 8 hours ago, opens new tab has discontinued testing a combination of an experimental antibody-based drug and...
Data-Based Insights About Merck & Co Inc
Stocks Register· 5 days agoMerck & Co Inc (NYSE:MRK) price on Thursday, May 09, rose 0.08% above its previous day’s close as an upside momentum from buyers pushed the stock’s value ...
Barrow, Hanley, Mewhinney & Strauss Bolsters Portfolio with Strategic Additions in Q1 2024
GuruFocus.com via Yahoo Finance· 2 hours agoThe top holdings were 3.68% in Vertiv Holdings Co (NYSE:VRT), 2.75% in Merck & Co Inc (NYSE:MRK),...
Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years
Simply Wall St. via Yahoo Finance· 3 days agoBy buying an index fund, investors can approximate the average market return. But if you pick the...
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Zacks· 5 days agoFree Report) is one of the stocks most watched by Zacks.com visitors lately. Shares of this pharmaceutical company have returned +2.2% over the past month versus the Zacks S&P 500 composite's ...
Tri-Cities doctor fined after prescribing ivermectin for COVID. 2nd physician charged
Tri-City Herald via Yahoo News· 2 days agoOne doctor joined in a lawsuit against the Washington Medical Commission with the help of the Silent...